some VanB isolates, and has excellent pharmacokinetic characteristics4). Antibiotic A40926 possesses the typical heptapeptide structure of the D-alanyl-D-alanine binding glycopeptides and is characterized by a Nacylaminoglucuronic acid and a mannose moiety bound to the aminoacids number 4 and 7 respectively (Figure 1 ). Several different related molecules have been identified in the A40926 complex3,5). The two major components of the complex are named B0 (formerly B) and B1 and are characterized respectively by an iso-C12:0 and a n-C12:0 acylic moiety bound to the aminoglucuronic acid of the antibiotic ( Figure 1 Packard mod 1100 HPLC system and detection was at 254nm. As internal standard an authentic sample of A40926 antibiotic was used.
LC-MS
The molecular weights of the A40926 and demannosyl-A40926 products were determined by mass spectrometry using a Finnigan LCQTM DUO instrument (Thermo Quest).
The experimental ESI conditions were as follows: Capillary 46V, Spray voltage 4.7kV. HPLC conditions were as above described.
Microbiological Activity Assay
The microbiological activity of the isolated antibiotics was compared in endpoint experiments as follows. Serial dilutions of the purified demannosyl-A40926 and of a real standard of A40926 were spotted on Nutrient agar plates (Difco). Plates were then overlaid with pre-cooled Nutrient agar inoculated with 107cfu/ml of S. haemolyticus 3902
antibiotic showing no inhibition on S. haemolyticus was considered as the endpoint of inhibition.
Results and Discussion
Clones of Nonomuraea sp. ATCC 39727 were overlaid with S. haemolyticus 3902 (clinical isolate, teicoplanin resistant) at a concentration of 107CFU/ml. In this condition, the parental strain, which is able to produce the antibiotic A40926, was unable to give inhibition halos on S.
haemolyticus. This overlay screening was in fact set up to To test the possibility of using strain A40DM in a standard fermentation process for the production of demannosyl-A40926, we performed fermentation and analysis of production in either strain ATCC 39727 and It was already reported the improved activity of semisynthetic demannosyl-A40926 against S. haemolyticus6).
The microbiological activity of demannosyl-A40926 was tested by agar diffusion as described in the section Material the previously reported improved activity of demannosyl-A40926 against coagulase negative Staphylococci.
The biosynthesis of glycopeptide aglycones has always been considered of primary importance due to their antimicrobial activity and to the fact that aglycones are a convenient starting material for chemical modifications.
The strain herein described is a good source for the one step production of demannosyl-A40926. Furthermore, the occurrence in the fermentation broth of demannosyl-A40926, which is identical in the rest of the structure to the A40926 molecule, indicates that coupling of mannose to A40926 occurs in the last phase of the biosynthesis. This is also consistent with the similarities in the production kinetics of either A40926 or demannosyl-A40926.
